Logo image of WGRX

WELLGISTICS HEALTH INC (WGRX) Stock Fundamental Analysis

NASDAQ:WGRX - Nasdaq - US9495031067 - Common Stock - Currency: USD

2.01  -0.32 (-13.73%)

After market: 2.02 +0.01 (+0.5%)

Fundamental Rating

0

Taking everything into account, WGRX scores 0 out of 10 in our fundamental rating. WGRX was compared to 102 industry peers in the Health Care Providers & Services industry. Both the profitability and financial health of WGRX have multiple concerns. WGRX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

WGRX had negative earnings in the past year.
In the past year WGRX has reported a negative cash flow from operations.
WGRX Yearly Net Income VS EBIT VS OCF VS FCFWGRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 -2M -4M -6M

1.2 Ratios

Looking at the Return On Assets, with a value of -67.52%, WGRX is doing worse than 92.16% of the companies in the same industry.
With a Return On Equity value of -875.32%, WGRX is not doing good in the industry: 84.31% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -67.52%
ROE -875.32%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
WGRX Yearly ROA, ROE, ROICWGRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 0 -200 -400 -600 -800

1.3 Margins

Looking at the Gross Margin, with a value of 8.49%, WGRX is doing worse than 78.43% of the companies in the same industry.
The Profit Margin and Operating Margin are not available for WGRX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 8.49%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
WGRX Yearly Profit, Operating, Gross MarginsWGRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024 0 -10 -20 -30

More info and screens

1

2. Health

2.1 Basic Checks

WGRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, WGRX has less shares outstanding
WGRX has a better debt/assets ratio than last year.
WGRX Yearly Shares OutstandingWGRX Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 10M 20M 30M 40M 50M
WGRX Yearly Total Debt VS Total AssetsWGRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

WGRX has an Altman-Z score of -1.38. This is a bad value and indicates that WGRX is not financially healthy and even has some risk of bankruptcy.
WGRX has a worse Altman-Z score (-1.38) than 85.29% of its industry peers.
WGRX has a Debt/Equity ratio of 1.43. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of WGRX (1.43) is worse than 68.63% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.43
Debt/FCF N/A
Altman-Z -1.38
ROIC/WACCN/A
WACC8.53%
WGRX Yearly LT Debt VS Equity VS FCFWGRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 5M 10M

2.3 Liquidity

A Current Ratio of 0.36 indicates that WGRX may have some problems paying its short term obligations.
The Current ratio of WGRX (0.36) is worse than 93.14% of its industry peers.
A Quick Ratio of 0.15 indicates that WGRX may have some problems paying its short term obligations.
WGRX has a Quick ratio of 0.15. This is amonst the worse of the industry: WGRX underperforms 94.12% of its industry peers.
Industry RankSector Rank
Current Ratio 0.36
Quick Ratio 0.15
WGRX Yearly Current Assets VS Current LiabilitesWGRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 10M 20M 30M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for WGRX have decreased strongly by -160.04% in the last year.
EPS 1Y (TTM)-160.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
WGRX Yearly Revenue VS EstimatesWGRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 5M 10M 15M

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

WGRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
WGRX Price Earnings VS Forward Price EarningsWGRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
WGRX Per share dataWGRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 -0.6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for WGRX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

WELLGISTICS HEALTH INC

NASDAQ:WGRX (5/30/2025, 8:00:01 PM)

After market: 2.02 +0.01 (+0.5%)

2.01

-0.32 (-13.73%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)05-12 2025-05-12
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner Change87.8%
Market Cap144.44M
AnalystsN/A
Price TargetN/A
Short Float %0.6%
Short Ratio0.14
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.98
P/FCF N/A
P/OCF N/A
P/B 32.25
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.8
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.05
FCFYN/A
OCF(TTM)-0.04
OCFYN/A
SpS0.4
BVpS0.06
TBVpS-0.47
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -67.52%
ROE -875.32%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 8.49%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.5
Health
Industry RankSector Rank
Debt/Equity 1.43
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.36
Quick Ratio 0.15
Altman-Z -1.38
F-Score5
WACC8.53%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-160.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-113.33%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-358.98%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-250.9%
OCF growth 3YN/A
OCF growth 5YN/A